General Information of Drug (ID: DMUGZMO)

Drug Name
RWJ-49815 Drug Info
Synonyms
2-[2-[4-(3,3,3-Triphenylpropoxy)phenyl]ethyl]guanidine; AC1LAN8D; SCHEMBL13339359; AJKCPFPHDCULCG-UHFFFAOYSA-N; 2-(4-(3,3,3-triphenylpropoxy)phenyl)ethylguanidine; 1-[2-[4-(3,3,3-triphenylpropoxy)phenyl]ethyl]guanidine; 2-[2-[4-(3,3,3-triphenylpropoxy)phenyl]ethyl]guanidine; RJW-57926
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Terminated [1]
Eating disorder 6B82 Investigative [2]
Obesity 5B81 Investigative [2]
Therapeutic Class
Antifungal Agents
Cross-matching ID
PubChem CID
516731
TTD Drug ID
DMUGZMO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CGP71683A DMRYC08 Obesity 5B81 Discontinued in Phase 3 [4]
Velneperit DMROSHN Obesity 5B81 Discontinued in Phase 2 [5]
S-234462 DM80P4U Obesity 5B81 Discontinued in Phase 1 [5]
Axovan-3 DM1JN6A Eating disorder 6B82 Discontinued in Phase 1 [2]
FR-79620 DMXR287 Diabetic complication 5A2Y Preclinical [6]
GW-594884A DMHUD27 Obesity 5B81 Preclinical [6]
NPY5RA-972 DMXUCSN Obesity 5B81 Preclinical [6]
AR-129330 DMUSYKG Discovery agent N.A. Investigative [7]
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] DMKANOH Discovery agent N.A. Investigative [8]
S-25585 DMBUD1M Eating disorder 6B82 Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SK509 DM73SC6 Discovery agent N.A. Investigative [3]
RWJ-49968 DMBOSGN Fungal infection 1F29-1F2F Investigative [9]
RWJ-61907 DMGUWFJ Fungal infection 1F29-1F2F Investigative [9]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Sporulation kinase A (Bact kinA) TTJVCG0 KINA_BACSU Inhibitor [3]
Neuropeptide Y receptor type 5 (NPY5R) TTY6EWA NPY5R_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009390)
2 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
3 Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem. 2002 Apr;10(4):855-67.
4 Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
5 Clinical pipeline report, company report or official report of Shionogi (2011).
6 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
7 Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
8 Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.
9 Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.